Wouldn’t it be great to be paid when your stocks skyrocket? You may believe that such a situation is implausible. However, this is not guaranteed. According to Wall Street, three dividend stocks might increase by 51% to 58% in the next 12 months.
1. Sanofi Stock
Some pharmaceutical companies have withstood the bear market. Sanofi stock (NYSE:SNY) is not one of them. Shares of the French pharmaceutical company have fallen nearly 20% this year, roughly in line with the performance of the S&P 500.
However, many Wall Street analysts remain bullish on Sanofi stock (NYSE:SNY). The stock’s average 12-month price objective represents a 51% upside potential.
Sanofi hasn’t been this inexpensive in a long time. Investors have been concerned about the company’s litigation relating to the heartburn medication Zantac. Taking action, the US Food and Drug Administration (FDA) medicine off the market in 2020 owing to concerns that it might raise the risk of cancer.
Analysts, though, seem to believe that these fears are exaggerated. After purchasing the over-the-counter rights to Zantac, Sanofi only promoted it for a few years. The corporation thinks it responded properly when possible safety risks were initially detected. It also claims that a rigorous investigation demonstrates that Zantac is safe to use.
If Wall Street is correct, Sanofi will rebound significantly next year. The dividend yield on the stock is about 4.4%. Sanofi compensates investors handsomely for holding out for a comeback.
2. Zoetis Stock
The price of Zoetis stock (NYSE:ZTS) has dropped over 40% year to date. On the other hand, analysts believe the animal health stock will significantly rebound. Zoetis’s consensus 12-month price objective is 53% higher than its current share price.
Sure, Zoetis confronts challenges like economic instability, generic competition, and a high US currency. However, the company’s business continues to thrive. Because of the strong prognosis for the remainder of the year, Zoetis even upped its full-year 2022 projection in August.
Wall Street is most likely excited about Zoetis’ companion animal health business. Because of the close relationships that exist between owners and their dogs, this company is almost recession-proof.
Investors may find Zoetis’ dividend yield of 0.88% unappealing. However, after its separation from Pfizer in 2013, the business has grown its dividend five times. Expect Zoetis’ dividend to expand more.
3. Trust for Medical Properties
Medical Properties Trust (MPW) has taken a significant hit this year. So far, in 2022, shares of the healthcare real estate investment trust (REIT) have fallen more than 50%. Have analysts gone insane? Nope. The stock’s average 12-month price objective represents a 58% upside potential.
Rising interest rates are bad news for real estate investment trusts. The rising rates make it more expensive for businesses to finance the acquisition of new properties. Medical Properties Trust is also concerned about the financial viability of its main tenant, Steward.
Healthcare REIT, on the other hand, is still lucrative and expanding. It has a robust balance sheet. Steward’s financial situation seems to be improving as well. Medical Properties Trust looks to be a good buy on Wall Street, with shares selling at less than six times forecast profits.
Analysts are clearly impressed by the REIT’s super-high dividend yield of over 10.6%. If Medical Properties Trust stock rises as expected, investors will be rewarded for their patience.
Featured Image – Megapixl © Winnond
Author Okoro Chinedu 
